Becky Gordon

Becky Gordon

Auto-generated profile, based on publicly available information

Becky Gordon

Usher Institute, Edinburgh Medical School, University of Edinburgh , Edinburgh

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2025 in eClinicalMedicine
Verified
Journal Article
Open access
DTDaira Trusinska
Daira Trusinska
BLBohee Lee
Bohee Lee
SFSohail Ferdous
Sohail Ferdous
HKHarley H.Y. Kwok
Harley H.Y. Kwok
BGBecky Gordon
Becky Gordon
TSTing Shi
Ting Shi
In clinical trials, recently introduced respiratory syncytial virus (RSV) immunisation products have shown high efficacy in preventing severe RSV outcomes. Implementing successful immunisation programmes is however key to realising these benefits in real-world settings. We aimed to investigate uptake of the long-acting monoclonal antibody nirsevimab, the RSV maternal vaccine, and RSV vaccines for older adults in countries where immunisation programmes have been introduced, and to explore how uptake varies between countries and population subgroups. In this systematic review and meta-analysis, we carried out four monthly searches in Medline, Embase, and Global Health databases for studies reporting uptake of nirsevimab, the RSV maternal vaccine, and RSV vaccines for older adults. We included population-based studies published between December 1, 2022 and February 5, 2025. Two independent reviewers screened studies, extracted data, and completed a risk of bias assessment using the Joanna Briggs Institute (JBI) Critical Appraisal Tools. We assessed uptake stratified by country and socio-demographic and clinical subgroups. Meta-analyses were conducted using random-effects modelling. PROSPERO registration number: CRD42025643585. We screened a total of 1267 studies, 43 of which met the inclusion criteria reporting data on over 1.38 million individuals from six countries. Nirsevimab uptake data were reported in 34 studies: 16 from Spain, eight from the United States, seven from France, one with combined data from Andorra and Spain, and one from each of Italy and Luxembourg. Our pooled estimates showed that nirsevimab uptake on population level was 90.1% (95% confidence interval (CI): 86.4–92.9) in Spain and 51.2% (95% CI: 29.3–72.7) in the United States during the 2023/24 RSV season. Uptake data for the RSV maternal vaccine and RSV vaccines for older adults were reported in five and eight studies, respectively, all from the United States. Meta-analysis showed population-level uptake of 30.5% (95% CI: 20.6–42.6) and 18.2% (95% CI: 10.8–28.9), respectively. Uptake varied across subgroups. Uptake of nirsevimab varied substantially between the countries that have implemented infant RSV immunisation programmes. Despite the limited number of studies and the lack of more accurate data at national level the low uptake estimates for RSV maternal vaccine and RSV vaccines for older adults are concerning. National, clinical, and public health initiatives are needed to increase uptake of RSV immunisation products and ensure maximum benefit to people currently at risk of severe RSV outcomes. 10.13039/501100023699 Health Data Research UK , Inflammation and Immunity Driver Programme.

8 December 2025 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
MBMarie de Bakker
Marie de Bakker
BGBecky Gordon
Becky Gordon
ASAnoop S V Shah
Anoop S V Shah
EBEric Boersma
Eric Boersma
DKDorien M Kimenai
Dorien M Kimenai
Current approaches to estimate cardiovascular risk for primary prevention of cardiovascular disease (CVD) are suboptimal and novel strategies that optimize and personalize risk predictions are needed. In this review, we provide an overview of the potential use of circulating cardiovascular biomarkers—C-reactive protein, growth differentiation factor 15, N-terminal pro B-type natriuretic peptide, and cardiac troponins—to improve CVD risk prediction in the general population. We present novel statistical approaches that dynamically capture risk to further optimize and personalize cardiovascular risk estimation systems. While all studied cardiovascular biomarkers are independently associated with CVD risk when using measurements from a single time-point, the added value they provide to traditional risk factors in terms of accuracy is modest. A dynamic risk prediction approach—such as joint modelling—that can incorporate changes in biomarkers and other risk factors over time may better capture the complexities of CVD development, enhancing CVD risk estimates. With the increasing adoption of electronic health records and commercially available assays for these circulating biomarkers, deploying such systems in clinical practice has become feasible. Future research should focus on the development and validation of multi-marker biomarker-driven dynamic risk prediction models, along with development of a standardized methodological approach for comparing performance of dynamic risk estimation systems against current static models. To facilitate its implementation in clinical practice, public health impact and cost-effectiveness needs to be assessed. Finally, optimizing screening intervals through a biomarker-driven dynamic risk approach may offer further improvement in individualizing primary CVD prevention strategies.

22 July 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
BGBecky Gordon
Becky Gordon
JNJoyce U Nyiro
Joyce U Nyiro
HNHarish Nair
Harish Nair
ZSZakariya Sheikh
Zakariya Sheikh
EKEsther Katama
Esther Katama
TSTing Shi
Ting Shi
Background: Acute lower respiratory tract infections (ALRIs) are a leading cause of pediatric mortality in low- and middle-income countries. In recent years, substantial research has been done to enhance risk stratification of children presenting with ALRIs, in a bid to improve health outcomes in resource-limited settings. We sought to analyze the performance of several pediatric ALRI risk scores in the prediction of mortality among children hospitalized with ALRIs in Kenya. Methods: We retrospectively analyzed the data of 2182 children aged 2–24 months who were admitted to Kilifi County Referral Hospital, Kenya with severe ALRIs between January 2015 and December 2024. We evaluated the performance of 6 ALRI risk scores (RISC [HIV-negative], mRISC, RISC-Malawi, PERCH, PREPARE, and ReSVinet) in this population. Additionally, we created and evaluated a modified version of the ReSVinet score by including nutrition status. Discrimination was assessed using the area under the receiver operating characteristic curve (AUROC). Results: The mid-upper arm circumference (MUAC) version of the RISC-Malawi score showed the highest discrimination for the outcome of in-hospital mortality (AUROC, 0.83; 95% confidence interval, .79–.86), whilst all other scores showed acceptable discrimination (AUROC, 0.70–0.79). The modification of ReSVinet to include nutrition status significantly improved its AUROC from 0.72 to 0.79. Conclusions: All risk scores showed at least fair performance in the prediction of in-hospital mortality within our dataset. The RISC-Malawi (MUAC) score appears to be the most promising candidate for future implementation; however, further research is needed to evaluate the calibration, feasibility, and clinical utility of these scores.